Streetbeat News

Analyst Ratings

BMRN

William Blair analyst Tim Lugo has downgraded Biomarin Pharmaceutical (NASDAQ:BMRN) from Outperform to Market Perform.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:29 am

MAS

RBC Capital analyst Mike Dahl has downgraded Masco (NYSE:MAS) from Outperform to Sector Perform, while slightly raising the price target from $79 to $80.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:21 am

CIVB

Hovde Group analyst Brendan Nosal has upgraded Civista Bancshares (NASDAQ:CIVB) from Market Perform to Outperform.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:18 am

QRVO

Exane BNP Paribas has downgraded Qorvo from Outperform to Neutral, setting a price target of $80.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:12 am

BA

Bernstein analyst Douglas Harned has downgraded Boeing from Outperform to Market Perform and reduced the price target from $195 to $169.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:03 am

LFUS

Benchmark analyst David Williams has reiterated a Hold rating on Littelfuse (NASDAQ:LFUS).

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 9:59 am

LXRX

Needham analyst Joseph Stringer has reiterated a Hold rating on Lexicon Pharmaceuticals (NASDAQ:LXRX).

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 9:57 am

NARI

Needham analyst Mike Matson has reiterated a Hold rating on Inari Medical (NASDAQ:NARI).

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 9:50 am

SSTK

Needham analyst Bernie McTernan has reiterated a Buy rating on Shutterstock (NYSE:SSTK) and maintained a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 9:48 am

HRMY

Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $52.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 9:46 am